Inhibrx Biosciences Files 8-K Report

TL;DR

Inhibrx Biosciences filed an 8-K with Reg FD and financial updates.

AI Summary

On May 24, 2024, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Ibex SpinCo, Inc. until January 11, 2024, is headquartered in La Jolla, California.

Why It Matters

This 8-K filing provides updates on Inhibrx Biosciences' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and regulatory information, not indicating any immediate operational or financial distress.

Key Players & Entities

• Inhibrx Biosciences, Inc. (company) — Registrant
• Ibex SpinCo, Inc. (company) — Former company name
• May 24, 2024 (date) — Date of report
• January 11, 2024 (date) — Date of name change
• La Jolla, CA (location) — Company headquarters

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share INXB The Nasdaq Stock Marke

Filing Documents

• tm243190d17_8k.htm (8-K) — 33KB
• tm243190d17_ex99-1.htm (EX-99.1) — 4854KB
• img_summary-4clr.jpg (GRAPHIC) — 47KB
• bc_program-4c.jpg (GRAPHIC) — 29KB
• img_agonisticantibody-4clr.jpg (GRAPHIC) — 47KB
• fc_phase1inbrx-4c.jpg (GRAPHIC) — 137KB
• fc_inbrx109phase1-4clr.jpg (GRAPHIC) — 139KB
• fc_phase2trialdesign-4c.jpg (GRAPHIC) — 116KB
• img_hexavalent-4clr.jpg (GRAPHIC) — 45KB
• fc_inbrx106studydesign-4clr.jpg (GRAPHIC) — 124KB
• bc_program1-4c.jpg (GRAPHIC) — 34KB
• bc_totalshareholder-4clr.jpg (GRAPHIC) — 54KB
• bc_netloss-4clr.jpg (GRAPHIC) — 47KB
• 0001104659-24-065140.txt ( ) — 6781KB
• inxb-20240524.xsd (EX-101.SCH) — 3KB
• inxb-20240524_lab.xml (EX-101.LAB) — 33KB
• inxb-20240524_pre.xml (EX-101.PRE) — 22KB
• tm243190d17_8k_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Inhibrx Biosciences, Inc., a Delaware corporation (the "Company"), previously filed with the U.S. Securities and Exchange Commission (the "SEC") a registration outstanding shares of the Company's common stock by Inhibrx, Inc. ("RemainCo") to holders of shares of RemainCo's common stock as of the distribution record date, on a pro rata basis (the "Distribution"), at a ratio of one share of the Company's common stock for every four shares of RemainCo's issued and outstanding common stock held on May 17, 2024, the distribution record date. On May 24, 2024, the Registration Statement was declared effective by the SEC. The Registration Statement includes a preliminary information statement that describes the Distribution and provides important information regarding the Company's business and management. The final information statement, dated May 24, 2024 (the "Information Statement"), is attached hereto as Exhibit 99.1. As further described in the Information Statement, time, on May 29, 2024 (the "Distribution Time"), and the closing of the previously announced merger of RemainCo with and into a wholly owned indirect subsidiary of Sanofi (the "Merger") is expected to occur on May 30, 2024, subject to the satisfaction or waiver of customary closing conditions. Beginning on May 28, 2024 and through the Distribution Time, shares of the Company's common stock are expected to begin trading on a "when-issued" basis on The Nasdaq Global Market ("Nasdaq") under the symbol "INXBV". On May 30, 2024, the first trading day following the consummation of the Distribution, shares of the Company's common stock are expected to begin trading on a "regular-way" basis on Nasdaq under the symbol "I

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Information Statement of Inhibrx Biosciences, Inc., dated May 24, 2024. 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements about Sanofi's proposed acquisition of RemainCo and INBRX-101, and RemainCo's related spin-off of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109, its existing pipeline and corporate infrastructure, which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks and costs relating to the separation of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109 and the consummation of the spin-off in the anticipated timeframe or at all; changes to the configuration of the INBRX-105, INBRX-106 and INBRX-109 businesses included in the separation if implemented; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting management's attention from the Company's ongoing business operation; negative effects of this announcement or the consummation of the proposed transaction on the market price of the Company's shares of common stock and/or operating results; significant transaction costs; risks associated with the discovery of unknown liabilities prior to or after the closing of the proposed transactions; the ri

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 24, 2024 INHIBRX BIOSCIENCES, INC. By: /s/ Kelly Deck Name: Kelly Deck Title: Chief Financial Officer and Treasurer 4

View Full Filing

View this 8-K filing on SEC EDGAR